Market

Amgen rebounds after denying bone safety concerns linked to obesity drug


Amgen office building in Mississauga, Ontario, Canada.

JHVEPhoto/iStock Editorial via Getty Images

Amgen (NASDAQ:AMGN) shares spiked in the premarket on Wednesday after the company ruled out concerns over loss of bone mineral density linked to its obesity candidate MariTide, which led to a ~7% decline in its share price in the previous session.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.